Please check your internet connection and try again.
# Montelukast-Levocetirizine (Fixed-Dose Combination)
## Overview
Montelukast is a selective leukotriene receptor antagonist (LTRA). Levocetirizine is a third-generation, non-sedating, H1-receptor antagonist (antihistamine). They are often combined for the management of allergic rhinitis and chronic urticaria where monotherapy is insufficient.
## Primary Indications
* Allergic Rhinitis (Seasonal and Perennial).
* Chronic Idiopathic Urticaria (often off-label when used in combination).
## Adult Dosing
* **Combination:** Typically 10 mg Montelukast / 5 mg Levocetirizine once daily, preferably in the evening.
## Pediatric Dosing
* **Ages 6–14 years:** Usually 5 mg Montelukast / 2.5 mg Levocetirizine once daily.
* **Under 6 years:** Combination products are generally not recommended; refer to weight-based monotherapy dosing guidelines.
* *Note: Dosing depends on specific regional formulations and local pediatric protocols.*
## Dose Adjustments
* **Renal Impairment:** Reduce Levocetirizine dose based on creatinine clearance (CrCl). If CrCl < 50 mL/min, the levocetirizine component typically requires frequency reduction or dose reduction.
* **Hepatic Impairment:** Monitor closely; no specific guidelines for the combination, but utilize caution in severe hepatic disease.
## Contraindications
* **Hypersensitivity:** Known hypersensitivity to montelukast, levocetirizine, or cetirizine.
* **Severe Renal Failure:** Patients with end-stage renal disease (CrCl < 10 mL/min) or hemodialysis.
## Adverse Effects
* **Montelukast:** Neuropsychiatric events (agitation, depression, sleep disturbances, suicidal ideation), headache, increased ALT/AST.
* **Levocetirizine:** Somnolence, fatigue, nasopharyngitis, dry mouth.
## Key Drug Interactions
* **CYP2C8/2C9/3A4 Inducers:** (e.g., Rifampin, Phenytoin) may decrease montelukast concentrations.
* **CNS Depressants:** Concurrent use of Alcohol, Opioids, or Benzodiazepines may enhance levocetirizine-induced sedation.
* **Theophylline:** Potential for altered clearance of montelukast; monitor clinical status.
## Monitoring
* **Neuropsychiatric:** Screen for mood changes or behavioral shifts.
* **Renal:** Periodic monitoring of renal function if impairment is present.
* **Efficacy:** Symptom control (nasal congestion, sneezing, itching).
## Clinical Pearls
* **Black Box Warning (FDA):** Montelukast includes a warning regarding serious neuropsychiatric events. Limit use to patients where other treatments are ineffective or inappropriate.
* **Timing:** Administer in the evening to optimize control of nocturnal symptoms associated with allergic rhinitis.
* **Administration:** May be taken with or without food.
* **Labeling:** Always verify if the specific combination product is approved for the intended age group in your jurisdiction, as many combination tablets are marketed for adult/adolescent use only.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify doses, contraindications, and drug-drug interactions using current clinical resources (e.g., Lexicomp, Micromedex) or the official package insert before prescribing or dispensing.
